IDWeek
IDWeek
October 04, 2013
1 min read
Save

Vancomycin frequently misused in neonatal ICU

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN FRANCISCO — More than 85% of the instances of vancomycin administration in a neonatal ICU were inappropriate, according to prospective study results presented at ID Week 2013.

The study included children aged at least 3 days admitted to the neonatal ICU at Children’s Memorial Hermann Hospital in Houston during a 5-month period from 2012 to 2013.

Appropriate use of vancomycin included treatment for methicillin-resistant Staphylococcus aureus, coagulase-negative staphylococci or ampicillin-resistant enterococci.

Researchers observed 137 administrations of antibiotics to 91 patients. Of them, 82 (90%) received vancomycin, for a total of 115 cases.

Of the 82 patients who received vancomycin, 45 (55%) received it for more than 2 days, accounting for 59 (51%) of the cases. Vancomycin was administered for a total of 557 days, equating to 0.6 days/1,000 patient-days.

However, only eight (14%) of these 59 cases were positive for MRSA (n=3), coagulase-negative staphylococcus (n=4) or an infection related to coagulase-negative staphylococci (n=1).

Vancomycin was frequently used in the treatment of clinical sepsis and necrotizing enterocolitis as empiric therapy, the researchers noted.

“Vancomycin is inappropriately utilized in more than 85% of antibiotic administration episodes in our neonatal ICU,” researchers wrote. “Despite culture data demonstrating low prevalence of MRSA and coagulase-negative staphylococcal infections, it is still utilized as the first-line agent for suspicion of sepsis as well as necrotizing enterocolitis. Interventions to decrease empiric, unnecessary vancomycin usage in the neonatal ICU should be developed.”

For more information:

Holzmann-Pazgal G. Abstract #161. Presented at: ID Week 2013; Oct. 2-6, 2013; San Francisco.

Disclosure: Some of the researchers report research funding from the University of Texas.